Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Investor Information

Company Information

Can-Fite BioPharma Ltd. (NYSE MKT: CANF)

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company is conducting Phase I, II and III clinical trials for numerous indications in the U.S., Europe and Israel. CF102, the Company’s liver cancer drug now in Phase II, has been granted Orphan Drug Status by the U.S. FDA and has shown proof of concept to potentially treat four other cancers. CF101, which is in Phase II and III to treat inflammatory and ophthalmic diseases, has an excellent safety profile with experience in over 1,000 patients. Can-Fite currently maintains 14 patent families that include 74 international patents issued and pending and its science is well-founded with articles in 48 peer reviewed journals.

Stock Information

Last Change Volume

Can-Fite's ADRs trade in the USA under the ticker CANFY and the ordinary shares trade on the Tel-Aviv Stock Exchange under the ticker CFBI.

More on CFBI »

Investor Relations

Corporate ProfileĀ®
Laurel Moody
646 810 0608

Quick Links

Recent News